mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas

European Journal of Cancer

Volumn 37, Issue 15, 2001, Pages 1839-1846

  Hagemann, T ^a   Gunawan, B ^a   Schulz, M ^a   Fuzesi L ^a   Binder, C ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cytogenetics; Matrix metalloproteases; Quantitative reverse transcriptase polymerase chain reaction; Renal cell carcinoma; Tissue inhibitors of metalloproteases

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER SIZE; CHROMOSOME 3P; CHROMOSOME DELETION; CLEAR CELL CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOGENETICS; DEREGULATION; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE LOCUS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY; KIDNEY CARCINOMA; KIDNEY PAPILLA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; GENE EXPRESSION; HUMANS; KARYOTYPING; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASES; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0034802191     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00215-5     Document Type: Article

References (41)

1. Matrix metalloproteinases in tumour invasion and metastasis
2. Regulation of matrix metalloproteinase expression in tumor invasion
3. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
4. Tissue inhibitors of metalloproteinases: Evolution, structure and function
5. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation - Regulation by TIMP-2 and TIMP-3
6. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2
7. Overview of matrix metalloproteinase expression in cultured human cells
8. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism
9. TIMP-2 growth-stimulatory activity: A concentration and cell type-specific response in the presence of insulin
10. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
11. A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitogenic stimulation, differentiation, and senescence
12. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas
13. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridisation
14. Matrilysin expression in human prostate carcinoma
15. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
16. Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival
17. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma
18. Classification of renal cell carcinoma
19. Grading of renal cell carcinoma
20. TNM staging of renal cell carcinoma
21. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
22. SV 40 transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages
23. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expressing in tumor cell lines and human tumor tissues
24. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors
25. Induction of inducible nitric oxide synthase is an essential part of TNF-α-induced apoptosis in MCF-7 and other epithelial tumor cells
26. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
27. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to overall survival of patients with gastric carcinomas
28. Stromelysin-3 gene expression in human cancer: An overview
29. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer
30. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
31. Matrix metalloproteinases and their inhibitors
32. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
33. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells
34. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2
35. High levels of messenger RNAs for tissue inhibitor of metalloproteinase (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
36. TIMP-1 and adverse prognosis in non-small cell lung cancer
37. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential
38. Cytogenetic analysis of epithelial renal-cell tumors: Relationship with anew histopathological classification
39. Cloning of the human tissue inhibitor of metalloproteinase-4 gene (TIMP4) and localization of the TIMP4 and Timp4 genes to human chromosome 3p25 and mouse chromosome 6, respectively
40. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas